Stocks · News reference

TD Cowen Maintains Hold on Quanterix, Lowers Price Target to $3

Aug 11, 2026, 4:05 PMBenzinga Newsdesk

TD Cowen analyst Dan Brennan maintains Quanterix (NASDAQ:QTRX) with a Hold and lowers the price target from $4 to $3.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncAug 27, 2026, 5:00 PMDelveinsight
Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight
The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.
Read original at globenewswire-inc
RHHBY ABT TMO DGX LH
BenzingaAug 24, 2026, 12:06 PMBenzinga Insights
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings came out 3
Read original at benzinga
AEMD CYPH ELOX JUNS KAPA
BenzingaAug 17, 2026, 12:24 PMBenzinga Newsdesk
Canaccord Genuity Maintains Hold on Quanterix, Lowers Price Target to $3
Canaccord Genuity analyst Kyle Mikson maintains Quanterix (NASDAQ:QTRX) with a Hold and lowers the price target from $4 to $3.
Read original at benzinga
QTRX